MPNs Day agenda TBC

Introduction & meeting objectives and keynote talks – Amer Zeidan

Session 1: CHIP/CCUS – Michael Savona and Uma Borate     

• The SEARCH CONSORTIUM: Looking for Answers in CHIP And CCUS; Zhuoer Xie
• Clonal hematopoiesis and transplantation outcomes; Coleman Lindsley
• Should CCUS be considered as lower risk MDS?; Uma Borate
• Putting it all together; Michael Savona

Panel discussion

Keynote talk:

Leveraging the icMDS combined database to answer timely and important questions on classification and risk stratification in MDS: Matteo Della Porta

Break

Session 2: CMML – Michael Savona and Valeria Santini                   

• RASopathies; Key Features of Ras-Family Mutated CMML, and Treatment Options; Mrinal Patnaik
• Approaches from the MDS/MPN IWG: ABNL MARRO, and beyond; Daniel Wiseman
• Elucidating the role of HMAs in CMML-A standard of care or not? Lisa Pleyer
• The Special Case of MDS/MPN-RS-T; Valeria Santini

Panel discussion

Session 3: Epigenetics and Splicing

Chairs: Valeria Santini and Elizabeth Griffiths                                    

• Oral hypomethylating agents in MDS-what is next?; Elizabeth Griffiths
• Updates in therapeutic combinations of epigenetic agents in MDS/AML; Aristoteles Giagounidis
• Pathophysiology and targeting of splicing factor mutant MDS and CMML; Jacqueline Boultwood
• Overview of the NIH Program for MDS; Alain Mina

Panel discussion

Lunch

Session 4: Inflammation and Immune interventions

Chairs: Andrew Wei and Rena Buckstein                                                                                                  

• Targeting inflammation & dysregulated innate immunity in MDS; Shahram Kordasti
• Updates in Vexas Syndrome; Carmelo Gurnari
• IRAK inhibitors in MDS and AML; Uwe Platzbecker
• How can we optimize transplant outcomes for MDS?; Charles Craddock
• What we have learn from AML immune contexture that can be relevant to MDS?;
  Leonido Luznik

Panel discussion

Session 5: Classification and risk stratification Updates

Chairs: Rena Buckstein and Maria Teresa Voso

• Roadmap for harmonization of classifications; Somedeb Ball
• Molecular data integration in prognostic tools; Elli Papaemmanuil
• Prognosis assessment in resource-limited countries; Maria Teresa Voso
• Predicting relapse risk in MDS post-transplant: Ready for primetime? Christopher Hourigan
• The Role of Classification versus Prognostication in MDS Patients; Robert Hasserjian

Panel discussion

Break

Session 6: Response assessment & regulatory considerations
Chairs:  Amer Zeidan & Kelly Norsworthy

Keynote talk: Proceedings from FDA/NCI workshop on drug development in MDS; Kelly Norsworthy

Panel discussion

• How can we measure disease modification in LR-MDS; Rami Komrokji
• Are molecular responses ready for prime time use in MDS? Katharina Götze
• IWG response criteria evolution for higher risk MDS; Amer Zeidan

Panel discussion

Day 1 Wrap-up

Session 7: TP53 aberrations and Secondary AML
Chairs: Valeria Santini & Andrew Wei 

• How to use TP53 status for clinical decisions in MDS?; Coleman Lindsley
• Therapies for secondary AML; Thomas Cluzeau
• Targeting the CD47-SIRPa axis in MDS/AML; David Sallman
• TP53 focused initiative in MDS MyeloMatch; Maximilian Stahl
• Putting it together: current and future perspectives in TP53 mutated AML; Andrew Wei

Panel discussion

Session 8: Advances in LR-MDS therapies
Chairs: Uwe Platzbecker & Olatoyosi Odenike   

• Telomerase inhibition; Uwe Platzbecker
• TGF pathway modulation; Lionel Ades
• Should lenalidomide become SOC in del5q LR-MDS before needing transfusions? María-Díez Campelo
• myeloMATCH efforts to move clinical trial development ahead in MDS; Olatoyosi Odenike
• Putting it together-how do I manage LR-MDS in 2023; Valeria Santini

Panel discussion

Break

Session 9: Updates in HR-MDS therapies
Chairs: Andrew Wei and Amer Zeidan

• IDH inhibitors- mono or combination therapy in MDS?;  Marie Sebert
• RARA agonists- Updates in use of RARA agonists in MDS?; Amy DeZern
• Updates on TIM3 targeting in MDS and AML?; Amer Zeidan
• Putting all together; New directions in management of HR-MDS Andrew Wei

Panel discussion

Session 10: Big data and quality of life measures
Chairs: Rena Buckstein and Mikkael Sekeres

• Should we include frailty and geriatric assessment in prognostic tools; Rena Buckstein
• The HARMONY Alliance: A Big Data platform for patients with hematologic malignancies; Guillermo Sanz
• Artificial Intelligence for MDS prognostication; Adrián Mosquera Orgueira
• QOL in MDS: what are its predictors and what does it predict?; Fabio Efficace
• How should we integrate quality of life as an endpoint in trials; Mikkael Sekeres

Panel discussion

End of meeting summary